Literature DB >> 16281988

Evasion of innate immunity by vaccinia virus.

I R Haga1, A G Bowie.   

Abstract

Vaccinia virus, a member of the Poxviridae, expresses many proteins involved in immune evasion. In this review, we present a brief characterisation of the virus and its effects on host cells and discuss representative secreted and intracellular proteins expressed by vaccinia virus that are involved in modulation of innate immunity. These proteins target different aspects of the innate response by binding cytokines and interferons, inhibiting cytokine synthesis, opposing apoptosis or interfering with different signalling pathways, including those triggered by interferons and toll-like receptors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16281988     DOI: 10.1017/S0031182005008127

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  44 in total

1.  Characterization of wild-type and mutant vaccinia virus M2L proteins' abilities to localize to the endoplasmic reticulum and to inhibit NF-kappaB activation during infection.

Authors:  Olivia Hinthong; Xiao-Lu Jin; Joanna L Shisler
Journal:  Virology       Date:  2008-01-10       Impact factor: 3.616

2.  Interleukin-6 has differential influence on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine.

Authors:  George Hui; Caryn Hashimoto
Journal:  Vaccine       Date:  2007-07-19       Impact factor: 3.641

3.  Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment.

Authors:  George S Hui; Caryn N Hashimoto
Journal:  Int Immunopharmacol       Date:  2008-04-03       Impact factor: 4.932

4.  M135R is a novel cell surface virulence factor of myxoma virus.

Authors:  John W Barrett; Joanna Sypula; Fuan Wang; Lindsay R Alston; Zhuhong Shao; Xiujuan Gao; Timothy S Irvine; Grant McFadden
Journal:  J Virol       Date:  2006-10-25       Impact factor: 5.103

5.  Poxvirus host range protein CP77 contains an F-box-like domain that is necessary to suppress NF-kappaB activation by tumor necrosis factor alpha but is independent of its host range function.

Authors:  Shu-Jung Chang; Jye-Chian Hsiao; Stephanie Sonnberg; Cheng-Ting Chiang; Min-Hsiang Yang; Der-Lii Tzou; Andrew A Mercer; Wen Chang
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

6.  Dose-dependent lymphocyte apoptosis following respiratory infection with Vaccinia virus.

Authors:  Nicole L Yates; Rama D Yammani; Martha A Alexander-Miller
Journal:  Virus Res       Date:  2008-08-23       Impact factor: 3.303

7.  The 29-nucleotide deletion present in human but not in animal severe acute respiratory syndrome coronaviruses disrupts the functional expression of open reading frame 8.

Authors:  Monique Oostra; Cornelis A M de Haan; Peter J M Rottier
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

8.  Proteomic screening of variola virus reveals a unique NF-kappaB inhibitor that is highly conserved among pathogenic orthopoxviruses.

Authors:  Mohamed R Mohamed; Masmudur M Rahman; Jerry S Lanchbury; Donna Shattuck; Chris Neff; Max Dufford; Nick van Buuren; Katharine Fagan; Michele Barry; Scott Smith; Inger Damon; Grant McFadden
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-18       Impact factor: 11.205

9.  Vaccinia virus protein C16 acts intracellularly to modulate the host response and promote virulence.

Authors:  Aodhnait S Fahy; Richard H Clark; Emily F Glyde; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2008-10       Impact factor: 3.891

10.  Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein.

Authors:  Samantha Cooray; Mohammad W Bahar; Nicola G A Abrescia; Colin E McVey; Nathan W Bartlett; Ron A-J Chen; David I Stuart; Jonathan M Grimes; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2007-06       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.